Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Drug Discovery & Development | Whitepapers & Reports

Revealing and retrieving highly potent IFN-? secretors using an Xdrop® single-cell format workflow based on double-emulsion droplets

19 May 2023
Bulk functional assays of immune cells miss highly potent cells within the population. This Xdrop single-cell format workflow for IFN-? secretion assessment reveals these highly potent individual cells, enabling their retrieval and expansion.
Open document in a new tab

Related Resources

FDA Grant Rare Pediatric Disease Designation to Omeros’s Antibody for C3 Glomerulopathy

Rare pediatric disease designation allows the company to access priority review from the FDA for a new drug application or biologics licence application.
Read More

Regeneron’s Bispecific Gets EU Approval After FDA Rejection

The approval means that the bispecific antibody odronextamab can be used to treat adult patients with relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in the EU.
Read More